Materials and Methods

HPLC profiling of Leuzea carthamoides extract
Solvents and chemicals
-Linolenic acid ( 99.0 %), a mixture of palmitic 40-51% and stearic acid, 49-54% acid, and oleic acid and palmitin ( 99.0 %) were purchased from Sigma-Aldrich. 20 Solid phase extraction (SPE) was done using Bakerbond SPE (C18) cartridges (Product No. 7020-03) activated with 100% methanol (3 x 5 mL) and conditioned using 20% aqueous acetonitrile (3 x 5 mL). Sample was loaded and fractions collected starting with 20% acetonitrile in water (2x 3 mL), increasing in 20% increments (collecting 2 x 3 mL each time) until 100 % acetonitrile was reached. The fractions were evaporated to dryness and redissolved in methanol and analysed.
TOF MS mass spectra were obtained on a MicroTOF mass spectrometer (Bruker Daoltonics) equipped with an ESI source. A solution of propan-2-ol/ H 2 O (1:1), 0.1% HCO 2 H and 5 µM NaOH was used as lockspray.
Chromatography and detection
Chromatography was performed on a Sunfire C18 column (3. 0-2 min, 25% A; 2-7 min, to 40% A, 7-90 min, to 100% A, 90-95 min 100% A. The flow rate was 0.5 mL/min and the injection volume was 20 µL. UV-vis spectra were recorded in the range of 210-700 nm at a spectral acquisition rate of 2 scans /s. ESI-MS conditions were as follows: spectra were recorded under ion charge control conditions (ICC 30000) at a scan speed of 13000 m/z /s with a Gauss filter width of 0.2 m/z. Nitrogen was used as drying gas at a flow rate of 10 L/min and as nebulizing gas at a pressure of 30 psi. The nebulizer temperature was set at 300°C. Both positive and negative ions were detected. The spectra were recorded in the range from m/z 100 to 800 amu; capillary voltage was set at 4500V, end plate offset at -500 V, capillary exit at -111.8 V, skimmer voltage at 60.0V and trap drive at 43.7. For ELSD detection, nitrogen was used as the nebulising gas at a flow rate of 1.5 L/min and a temperature of 55°C. Signal gain was set to 4 with an analog output at 20000 units/Volt and signal gain was set on.
Semi-preparative isolation was performed on a Sunfire C18 column (5 m; 150 x 10.0 mm I.D.; Waters) equipped with a guard column (5 m; 10 x 10 mm I.D). The flow rate was 5 mL/min and the injection volume was 500 µL.
Fig. 1S. LC-MS-UV-ELSD analysis of Leuzea carthamoides extract. HPLC traces were obtained with the following detectors: ELSD (green); PDA (black); ESI-MS positive ion 7mode (red); ESI-MS negative ion mode (blue).
Strategy of compound identification
A literature review was undertaken to identify all compounds previously isolated from Leuzea carthamoides. To date 63 compounds have been isolated and characterised. This list provided the starting point in the assignment of known compounds in the chromatogram. Peaks were assigned with the aid of elemental formula calculated from TOF-MS, fragmentation pattern in low-resolution MS, UV spectral data, ELSD signals for compounds without chromophor, and by co-chromatography of selected reference compounds. Assignments and spectral data are given in Table 1S . replicates per test concentration.
The acute cytotoxic potential of Leuzea extract was determined with the Cytotoxicity Detection Kit (LDH) (Roche Diagnostics). No acute cytotoxicity could be found at concentrations up to 100 µg/mL.
RNA isolation
Cells were washed twice with PBS and total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) including on column DNase digestion according to the standard protocol.
Quantity and purity of the obtained total RNA samples were determined by UV spectroscopy.
RNA quality was controlled by gel electrophoresis on 1.5% agarose, stained with ethidium bromide (1 µg/mL). RNA was stored at -80 °C until use.
Array hybridization
Affymetrix according to the manufacturer´s protocol (manual version 700217 rev 3), with minor modification. Briefly, 5 µg of total RNA was converted into cDNA by using the T7- 
Primary array data analysis
Initial data analysis was performed using the Affymetrix Microarray Suite v5.1 software, setting the scaling of all probe sets to a constant value of 500 for each GeneChip. Because of the better implemented normalisation algorithm, data were further normalized using RMAExpress software in release 0.4 alpha 7
(http://www.stat.berkeley.edu/users/bolstad/RMAExpress/RMAExpress.html) [15] , [16] .
With RMAExpress all arrays were visually checked. There were no obvious failures on the chips. RMAExpress is using enhanced quantile normalization [15] . All 8 experiments (4 different treatments -Leuzea root extract, estradiol, tamoxifen and DMSO -in duplicate)
were normalized together. Data were then exported to MS-Excel sheets. We used both the log as well as the natural output. All further comparisons and analyses are based on these RMAExpress outputs. Significantly regulated (= differentially expressed) genes were determined using the following criteria: (I) The signal intensity is higher than the median of all signal intensities on the array and (II) in both independent duplicate experiments the fold change vs. DMSO control is larger than 1.5.
Real-time RT-PCR
Total RNA (5 µg) from each sample was transcribed into cDNA with SuperScript III reverse transcriptase (Invitrogen) and a 1:1-mixture of random hexamers (Promega) and oligo-dT (20) primers ( Abbreviations:
CDCA7, cell division cycle associated 7; CSTA, cystatin A (stefin A); DAB2, disabled homolog 2, mitogen responsive phosphoprotein (Drosophila) (Differentially expressed in ovarian cancer 2); DDA3, differential display and activated by p53 (proline/serine-rich coiled-coil 1); DKK1, dickkopf homolog 1 (Xenopus laevis); DLG7, discs, large homolog 7 (Drosophila); ECT2, epithelial cell transforming sequence 2 oncogene; EDN1, endothelin 1; ERBB3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (Tyrosine KinaseType Cell Surface Receptor HER3); IGFBP5, insulin-like growth factor binding protein 5; KIAA0101, KIAA0101 gene product (p15(PAF) protein; OEATC-1); KIF14, kinesin family member 14; MTSS1, metastasis suppressor 1; NRP1, neuropilin 1; OKL38, pregnancy-induced growth inhibitor; RET, rearranged during transfection (ret) proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease); S100P, S100 calcium binding protein; SAT, spermidine/spermine N1-acetyltransferase; SYNPO2, synaptopodin 2 (myopodin); VEGF, vascular endothelial growth factor; WWOX, WW domain containing oxidoreductase Abbreviations: BIRC5, baculoviral IAP repeat-containing 5; CCNE2, cyclin E2; DDIT4, DNA-damageinducible transcript 4; DNAJB9, DnaJ (Hsp40) homolog, subfamily B, member 9; E2F2, E2F transcription factor 2; GADD45A, growth arrest and DNA-damage-inducible, alpha; GREB1, GREB1 protein; PCNA, Proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor.
